John Larson, MD
Interventional Pain Medicine · Batesville, ARNPI 1104864354
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $955 of the $1,490 with a category attached, or 64.1%. 17 manufacturers reported payments, led by Tersera Therapeutics LLC at 43.5% of the total. 2025 is the largest year on record at $687, 2.0 times the $337 reported in 2019. That places this record below the midpoint for interventional pain medicine clinicians in AR, where the typical reported total is $3,706.
Across 54 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tersera Therapeutics LLC$649
- Spinal Simplicity, LLC$261
- Pacira Therapeutics, Inc.$177
- AbbVie$124
- Medtronic$69
- Nalu Medical, Inc.$34
- plus $176 from 11 others
What the payments were for
- Travel & lodging$23616%
- Food & beverage$95564%
- Education$30020%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tersera Therapeutics LLC | 25 | $649 |
| Spinal Simplicity, LLC | 2 | $261 |
| Pacira Therapeutics, Inc. | 4 | $177 |
| AbbVie(2 entities) | 8 | $124 |
| Medtronic | 2 | $69 |
| Nalu Medical, Inc. | 2 | $34 |
| Stryker | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Averitas Pharma Inc. | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $14 |
| Pfizer | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
| Daiichi Sankyo Inc. | 1 | $11 |
| Kinex Medical Company LLC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HA MINUTEMAN G3-R$236
- Zilretta$120
How this compares
$1,490 in reported general payments places this provider in the 30th percentile of 29 interventional pain medicine providers in Arkansas.
See all interventional pain medicine providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 652 | $17,699 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 439 | $11,510 |
| Pregabalin | 282 | $8,224 |
| Tizanidine Hcl | 593 | $7,979 |
| MovantikNaloxegol Oxalate | 14 | $7,125 |
| Gabapentin | 319 | $4,117 |
| Oxycodone Hcl | 118 | $2,166 |
| Morphine Sulfate | 39 | $1,522 |
| Cyclobenzaprine Hcl | 124 | $1,438 |
| Morphine Sulfate ErMorphine Sulfate | 37 | $1,321 |
| Methadone Hcl | 80 | $1,122 |
| Celecoxib | 30 | $904 |
| Baclofen | 63 | $730 |
| Fentanyl | 12 | $638 |
| Methocarbamol | 25 | $519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $19 | $7,12514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 29 interventional pain medicine providers in Arkansas.
Other interventional pain medicine in Batesville
- Meraj SiddiquiBatesville$4K
- Teddy ShieldsBatesville$2K
- Raja Hassan ImtiazBatesville$750
- Todd BesselievreBatesville$313
- Samuel TurnerBatesville$94
- Sameer JainBryant$56K
- Ryan KrafftMountain Home$51K
- Robert CannonFayetteville$15K
- Amir QureshiLittle Rock$14K
- Brett WhatcottFort Smith$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.